Supplementary Online Content

Li J, Patil D, Davies BJ, Filson CP. Trends in urethral suspension with robotic prostatectomy procedures following Medicare payment policy changes. *JAMA Netw Open*. 2022;5(10):e2233636. doi:10.1001/jamanetworkopen.2022.33636

eFigure 1. Proportion of Patients With a Diagnosis of Urinary Incontinence Before Radical Prostatectomy Based on Receipt of Urethral Suspension
eFigure 2. Median Payments for Robotic Prostatectomy Episodes Based on Insurance Type and Use of Urethral Suspension
eTable 1. Men Treated With Robotic Prostatectomy With or Without Payment for Urethral Suspension
eTable 2. Estimates From the Multivariable Logistic Regression Model
eTable 3. Results of Interrupted Time-Series Analyses

This supplementary material has been provided by the authors to give readers additional information about their work.
eFigure 1. Proportion of Patients With a Diagnosis of Urinary Incontinence Before Radical Prostatectomy Based on Receipt of Urethral Suspension
**eFigure 2.** Median Payments for Robotic Prostatectomy Episodes Based on Insurance Type and Use of Urethral Suspension

- **Commercial Insurance:**
  - Urethral Suspension: $3,678
  - No Urethral Suspension: $3,322
- **Medicare Supplemental Insurance:**
  - Urethral Suspension: $2,927
  - No Urethral Suspension: $2,379
### eTable 1. Men Treated With Robotic Prostatectomy With or Without Payment for Urethral Suspension

| Covariate                  | No Urethral Suspension (n = 84,422) | Urethral Suspension (n = 3,352) |
|----------------------------|------------------------------------|---------------------------------|
| **Time Period**            |                                    |                                 |
| 2009–2012                  | 45,559 (98.3)                      | 793 (1.7)                       |
| 2013–2015                  | 21,821 (95.9)                      | 929 (4.1)                       |
| 2016–2017                  | 9,412 (91.5)                       | 878 (8.5)                       |
| 2018–2019                  | 7,630 (91.0)                       | 752 (9.0)                       |
| **Age (years)**            |                                    |                                 |
| 40–54                      | 17,584 (96.4)                      | 648 (3.6)                       |
| 55–59                      | 22,525 (96.0)                      | 950 (4.0)                       |
| 60–64                      | 27,972 (95.8)                      | 1,225 (4.2)                     |
| 65–69                      | 10,463 (96.9)                      | 335 (3.1)                       |
| 70+                        | 5,878 (96.8)                       | 194 (3.2)                       |
| **Health Plan**            |                                    |                                 |
| Comprehensive              | 6,740 (96.2)                       | 265 (3.8)                       |
| HDHP/CDHP                  | 8,152 (95.2)                       | 411 (4.8)                       |
| HMO                        | 8,377 (96.2)                       | 331 (3.8)                       |
| POS/POS w/cap              | 6,060 (95.7)                       | 271 (4.3)                       |
| PPO/EPO                    | 51,033 (96.3)                      | 1,976 (3.7)                     |
| **Region**                 |                                    |                                 |
| Northeast                  | 16,363 (96.0)                      | 683 (4.0)                       |
| North Central              | 22,391 (97.0)                      | 684 (3.0)                       |
| South                      | 32,418 (95.3)                      | 1,602 (4.7)                     |
| West                       | 13,232 (97.2)                      | 380 (2.8)                       |
| Unknown                    | 18 (85.7)                          | 3 (14.3)                        |
| **Population of MSA (2015)** |                                    |                                 |
| Not in MSA                 | 12,681 (97.2)                      | 367 (2.8)                       |
| <250,000                   | 6,941 (96.7)                       | 237 (3.3)                       |
| 250,000–749,999            | 14,856 (96.5)                      | 540 (3.5)                       |
| 750,000+                   | 49,944 (95.8)                      | 2,208 (4.2)                     |
| **Payer Type**             |                                    |                                 |
| Commercial                 | 68,081 (96.0)                      | 2,823 (4)                       |
| Medicare Supplemental      | 16,341 (96.9)                      | 529 (3.1)                       |

© 2022 Li J et al. JAMA Network Open.
eTable 2. Estimates From the Multivariable Logistic Regression Model

| Covariate                        | OR (95% CI)       |
|---------------------------------|-------------------|
| **Year of surgery**             |                   |
| 2009 – 2012                     | **0.19 (0.17-0.21)** |
| 2013 – 2015                     | **0.46 (0.42-0.51)** |
| 2016 – 2017 Reference           |                   |
| 2018 – 2019                     | **1.06 (0.96-1.18)** |
| **Health Plan**                 |                   |
| HMO                             | Ref               |
| Comprehensive                   | **1.25 (1.05-1.49)** |
| HDHP/CDHP                       | **0.93 (0.80-1.08)** |
| POS/POS w/ capitation           | **1.03 (0.88-1.22)** |
| PPO/EPO                         | **1.09 (0.97-1.23)** |
| **Region**                      |                   |
| South                           | Ref               |
| Northeast                       | **0.87 (0.79-0.96)** |
| North Central                   | **0.66 (0.60-0.72)** |
| West                            | **0.60 (0.53-0.67)** |
| Unknown                         | **3.65 (1.08-12.35)** |
| **Population of MSA**           |                   |
| <250,000                        | Ref               |
| 250,000 – 749,999               | **1.05 (0.89-1.23)** |
| 750,000+                        | **1.25 (1.08-1.44)** |
| Non-MSA                         | **0.83 (0.70-0.99)** |
**eTable 3. Results of Interrupted Time-Series Analyses**

|                      | Urethral Suspension | Pelvic Lymphadenectomy |
|----------------------|---------------------|------------------------|
|                      | 2012 – 2015         | 2016 – 2019            | 2012 – 2015         | 2016 – 2019         |
| **Δ% per quarter**   | p                   | **Δ% per quarter**     | p                   | **Δ% per quarter**  | p                   |
| Commercial           | 0.29 (0.21 – 0.37)  | <0.001                 | 0.06 (-0.08 – 0.21) | 0.382 (0.62 – 1.07) | <0.001              | 0.53 (0.33 – 0.74)  | <0.001              |
| Medicare Supplemental| 0.29 (0.17 – 0.41)  | <0.001                 | -0.08 (-0.28 – 0.13)| 0.452 (0.96 – 1.49) | <0.001              | 0.36 (-0.07 – 0.78) | 0.099               |
| Δ-Δ                  | 0.00 (-0.15 – 0.14) | 0.971                  | 0.14 (-0.11 – 0.39) | 0.264 (-0.73 – 0.03) | 0.032               | 0.18 (-0.30 – 0.65) | 0.461               |